BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 20362199)

  • 1. Antibodies to serotype 9V exhibit novel serogroup cross-reactivity following infant pneumococcal immunization.
    Licciardi PV; Balloch A; Russell FM; Mulholland EK; Tang ML
    Vaccine; 2010 May; 28(22):3793-800. PubMed ID: 20362199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants.
    Yu X; Gray B; Chang S; Ward JI; Edwards KM; Nahm MH
    J Infect Dis; 1999 Nov; 180(5):1569-76. PubMed ID: 10515817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant.
    Wuorimaa T; Dagan R; Väkeväinen M; Bailleux F; Haikala R; Yaich M; Eskola J; Käyhty H
    J Infect Dis; 2001 Nov; 184(9):1211-5. PubMed ID: 11598848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.
    Soininen A; Nohynek H; Lucero M; Jousimies K; Ugpo J; Williams G; Käyhty H;
    Vaccine; 2009 May; 27(20):2680-8. PubMed ID: 19428879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model.
    Skinner JM; Indrawati L; Cannon J; Blue J; Winters M; Macnair J; Pujar N; Manger W; Zhang Y; Antonello J; Shiver J; Caulfield M; Heinrichs JH
    Vaccine; 2011 Nov; 29(48):8870-6. PubMed ID: 21964055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers.
    Goldblatt D; Southern J; Ashton L; Richmond P; Burbidge P; Tasevska J; Crowley-Luke A; Andrews N; Morris R; Borrow R; Cartwright K; Miller E
    Pediatr Infect Dis J; 2006 Apr; 25(4):312-9. PubMed ID: 16567982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B.
    Saeland E; Jakobsen H; Ingolfsdottir G; Sigurdardottir ST; Jonsdottir I
    J Infect Dis; 2001 Jan; 183(2):253-260. PubMed ID: 11110649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
    Bryant KA; Block SL; Baker SA; Gruber WC; Scott DA;
    Pediatrics; 2010 May; 125(5):866-75. PubMed ID: 20435707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional antibodies to the O-acetylated pneumococcal serotype 15B capsular polysaccharide have low cross-reactivities with serotype 15C.
    Rajam G; Carlone GM; Romero-Steiner S
    Clin Vaccine Immunol; 2007 Sep; 14(9):1223-7. PubMed ID: 17609392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumococcal antibodies in a child with type 14 pneumococcal conjugate vaccine failure.
    O'Brien KL; Moïsi J; Romero-Steiner S; Holder P; Carlone GM; Reid R; Santosham M
    Vaccine; 2009 Mar; 27(12):1863-8. PubMed ID: 19171175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-reactivity of antibodies to type 6B and 6A polysaccharides of Streptococcus pneumoniae, evoked by pneumococcal conjugate vaccines, in infants.
    Väkeväinen M; Eklund C; Eskola J; Käyhty H
    J Infect Dis; 2001 Sep; 184(6):789-93. PubMed ID: 11517443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of a heptavalent pneumococcal conjugate vaccine in Apache and Navajo Indian, Alaska native, and non-native American children aged <2 years.
    Miernyk KM; Parkinson AJ; Rudolph KM; Petersen KM; Bulkow LR; Greenberg DP; Ward JI; Brenneman G; Reid R; Santosham M
    Clin Infect Dis; 2000 Jul; 31(1):34-41. PubMed ID: 10913393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
    Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgG levels against 13-valent pneumococcal conjugate vaccine serotypes in non pneumococcal conjugate vaccine immunized healthy Japanese and intravenous immunoglobulin preparations.
    Takahashi Y; Ishiwada N; Hishiki H; Tanaka J; Akeda Y; Shimojo N; Oishi K; Kohno Y
    J Infect Chemother; 2014 Dec; 20(12):794-8. PubMed ID: 25242584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional antibodies elicited by an 11-valent diphtheria-tetanus toxoid-conjugated pneumococcal vaccine.
    Puumalainen T; Ekström N; Zeta-Capeding R; Ollgren J; Jousimies K; Lucero M; Nohynek H; Käyhty H
    J Infect Dis; 2003 Jun; 187(11):1704-8. PubMed ID: 12751027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 22-plex chemiluminescent microarray for pneumococcal antibodies.
    Pickering JW; Hoopes JD; Groll MC; Romero HK; Wall D; Sant H; Astill ME; Hill HR
    Am J Clin Pathol; 2007 Jul; 128(1):23-31. PubMed ID: 17580269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease.
    Vernacchio L; Romero-Steiner S; Martinez JE; MacDonald K; Barnard S; Pilishvili T; Carlone GM; Ambrosino DM; Molrine DC
    J Infect Dis; 2000 Mar; 181(3):1162-6. PubMed ID: 10720547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Essential criteria for evaluation of pneumococcal conjugate vaccine candidates.
    Paradiso P
    Vaccine; 2009 Aug; 27 Suppl 3():C15-8. PubMed ID: 19683657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.